Project description
Unveiling the role of epigenetics in resistance to prostate cancer therapy
Testosterone and other androgen hormones exert their function by binding to the androgen receptor (AR) that acts as a transcription factor and activates the expression of specific target genes. In prostate cancer, inhibition of AR signalling constitutes the backbone of therapy, but resistance eventually develops. The EU-funded RegARcis project is investigating the mechanism underlying this resistance by focussing on chromatin-remodelling complexes. In particular, scientists will study the switch/sucrose non-fermentable (SWI/SNF) factors implicated in nucleosome rearrangement and chromatin accessibility. The idea is to determine potential redistribution of AR binding sites that may explain therapy resistance in advanced stages of the disease.
Objective
The significance of epigenetic deregulation is a very hot topic in current prostate cancer (PC) research. New mutations have been identified in several epigenetic regulators known for their interaction with the AR. In fact, the role of chromatin remodeling factors facilitating enhancer-promoter cooperation in the formation of the AR transcriptional complex has long been demonstrated. Accordingly, the marked redistribution of AR binding sites (cistrome) during tumorigenesis is arguably the most recurrent genetic or epigenetic alterations in PC. Thus, this MCSA project aims at elucidating the role of the SWI/SNF chromatin-remodeling complex in the emergence of resistance to anti-AR signaling inhibitors. This is of utmost importance as resistance to AR signaling inhibition is arguably the principle hallmark of lethal prostate cancer. To this end, I aim at (i) investigating the SWI/SNF dependent chromatin accessibility and AR cistrome; and at (ii) assessing the actionability of SWI/SNF interacting partners in castration resistance prostate cancer (CRPC). In short, this MSCA proposal will help to define the repertoire of SWI/SNF coregulators in CRPC and to determine the extent of AR cistrome remodeling to envision new therapeutic strategies and help predict treatment response.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology prostate cancer
- natural sciences biological sciences genetics mutation
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2019
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
08908 L'Hospitalet De Llobregat
Spain
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.